Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Oct 2016 Status changed from suspended to active, no longer recruiting.
- 22 Jun 2016 Status changed from recruiting to suspended.